Thompson Siegel & Walmsley LLC Purchases 517 Shares of Abbott Laboratories (NYSE:ABT)

Thompson Siegel & Walmsley LLC boosted its position in Abbott Laboratories (NYSE:ABT) by 18.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,395 shares of the healthcare product maker’s stock after buying an additional 517 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Abbott Laboratories were worth $387,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. LPL Financial LLC increased its stake in shares of Abbott Laboratories by 4.0% in the 3rd quarter. LPL Financial LLC now owns 1,449,611 shares of the healthcare product maker’s stock valued at $165,270,000 after acquiring an additional 55,188 shares in the last quarter. John G Ullman & Associates Inc. grew its holdings in Abbott Laboratories by 0.3% in the third quarter. John G Ullman & Associates Inc. now owns 30,617 shares of the healthcare product maker’s stock worth $3,491,000 after purchasing an additional 90 shares during the period. German American Bancorp Inc. raised its holdings in shares of Abbott Laboratories by 8.1% during the third quarter. German American Bancorp Inc. now owns 84,420 shares of the healthcare product maker’s stock valued at $9,625,000 after purchasing an additional 6,352 shares during the period. America First Investment Advisors LLC boosted its position in shares of Abbott Laboratories by 1.8% during the 3rd quarter. America First Investment Advisors LLC now owns 186,850 shares of the healthcare product maker’s stock worth $21,303,000 after purchasing an additional 3,219 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Abbott Laboratories by 12.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 400,535 shares of the healthcare product maker’s stock valued at $45,665,000 after buying an additional 43,806 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity

In other news, CEO Robert B. Ford sold 141,679 shares of Abbott Laboratories stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the transaction, the chief executive officer now owns 220,059 shares in the company, valued at $25,617,068.19. This trade represents a 39.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the subject of a number of research reports. Morgan Stanley raised their price objective on Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 17th. Edward Jones lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Barclays raised their price objective on shares of Abbott Laboratories from $143.00 to $149.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada upped their target price on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Citigroup lifted their price target on Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $130.07.

Abbott Laboratories Trading Up 0.4 %

Shares of Abbott Laboratories stock opened at $117.76 on Friday. The stock has a fifty day moving average price of $115.58 and a 200-day moving average price of $109.88. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The firm has a market cap of $204.25 billion, a PE ratio of 35.79, a P/E/G ratio of 2.76 and a beta of 0.72. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $121.64.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, topping the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The business had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. During the same quarter in the previous year, the firm posted $1.14 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 1.87%. The ex-dividend date was Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 66.87%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.